Dr. Chaft on Ongoing Pivotal Trials in EGFR-Mutant NSCLC

Jamie E. Chaft, MD
Published: Wednesday, Apr 19, 2017



Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

The most anticipated trial is the FLAURA study, which is exploring first-line osimertinib (Tagrisso) versus erlotinib (Tarceva) and gefitinib (Iressa) in patients with EGFR T790M-mutant NSCLC, Chaft explains.

However, the one caveat is that the trial’s primary endpoint is progression-free survival, and researchers question whether osimertinib will demonstrate an overall survival advantage. Furthermore, it is unclear whether they should utilize a first- or second-generation drug after osimertinib or if there will be new drugs available that are specifically targeted at the time of progression on osimertinib.
 
SELECTED
LANGUAGE


Jamie E. Chaft, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses pivotal ongoing clinical trials in the landscape of EGFR-mutant non–small cell lung cancer (NSCLC).

The most anticipated trial is the FLAURA study, which is exploring first-line osimertinib (Tagrisso) versus erlotinib (Tarceva) and gefitinib (Iressa) in patients with EGFR T790M-mutant NSCLC, Chaft explains.

However, the one caveat is that the trial’s primary endpoint is progression-free survival, and researchers question whether osimertinib will demonstrate an overall survival advantage. Furthermore, it is unclear whether they should utilize a first- or second-generation drug after osimertinib or if there will be new drugs available that are specifically targeted at the time of progression on osimertinib.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: How to Use Liquid Biopsies Throughout the Lung Cancer Treatment Continuum OnlineJan 31, 20191.5
Community Practice Connections™: Current Status and the Future Potential of CAR T-Cell Therapy for Lymphoid Malignancies: The Experts Weigh-In on Recent Data and Clinical ExperienceJan 31, 20192.0
Publication Bottom Border
Border Publication
x